20 96

Cited 0 times in

Holmium-166 therapy of malignant and benign diseases.

Park, CH
Materials science forum, 315-317257-261, 1999
Journal Title
Materials science forum
Holmium-166 (Ho-166), one of the lanthanide radionuclides and produced upon neutron irradiation of naturally abundant Ho-165, is an almost ideal radionuclide for therapeutic purposes. The reasons for this are; 1) it is a strong beta emitter (Emax = 1.86 MeV) with maximum range in soft-tissue of 8.4mm, 2) it has a short physical half-life of 26.9 hours, 3) it emits a gamma photon (81 keV, 5.4%) that can be used for external imaging of post-therapy monitoring purpose. Clinical trials of Ho-166 therapy for various malignancies and benign conditions are under way in Korea, 166Ho(NO3) solution is applied into the balloon following percutaneous transfemoral coronary angioplasty (PTCA) in an attempt to inhibit neointimal hyperplasia incident to ballooning injury. Chitosan obtained by deacetylation of naturally abundant Chitin is complexed with Ho-166 by mixing acidic Chitosan solution at a room temperature with higher than 99% labelling yield. The Ho-166 complex is stable in vitro and vivo. Another benign condition, rheumatoid joint disease, is treated by local administration of the agent into the knee joint for radionuclide synovectomy. Malignant conditions being treated with Ho-166-CHICO (Chitosan complex) include cystic brain tumours, malignant ascites and pleural effusion, hepatocellular carcinomas, recurrent melanoma and recurrent rectal carcinomas. Our clinical experience with Ho-166 or Ho-166-CHICO therapy is presented.
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Nuclear Medicine & Molecular Imaging
AJOU Authors
박, 찬희
Files in This Item:
Full-Text Not Available.txtDownload
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.